Hanmi Science Co., Ltd.

South Korea

  • 1m
  • 3m
  • 6m
  • 1y
  • 2y
  • 5y
Feb 22, 2018
Prev close: 86,000
Feb 22, 2018
Market cap:
Market cap(USD):
Shares: 63.49M

Currency in KRW

Company profile

Market(Ticker): KRX(008930)
Health Technology
Pharmaceuticals: Other
Full time employees: --

Business summary

Hanmi Science Co., Ltd. is a holding company that engages in the management of its subsidiaries. It is mainly engaged in the manufacturing and selling of pharmaceutical ingredients and intermediates. The company was founded on June 15,1973 and is headquartered in Hwaseong, South Korea.

Company background

Hanmi Science is a holding company with two core subsidiaries: Hanmi Pharmaceutical, which develops and produces medicines, and Online Pharm, a drug wholesaler. In recent years, the South Korean group has been actively developing new drugs. It has also accelerated overseas expansion, including by setting up a unit in Beijing.

The company's market capitalization puts it in the top tier of South Korean drug companies, alongside Celltrion.

The group was established in 1973 as Hanmi Pharmaceutical. It strengthened its presence in the drug development game in the 2000s. About 20% of sales are reinvested in research and development.

Hanmi has been focusing on clinical trials for diabetes treatments. It expects the diabetes drug market to grow at an average annual pace of over 6% from 2014 to 2023, nearly doubling in size to $42 billion.

The company's operations include original design manufacturing services for major international drugmakers, including France's Sanofi. For this, Hanmi uses a plant in Hwaseong, Gyeonggi Province. It also runs a facility for antibiotics and biotechnology in Pyeongtaek, in the same province.

Hanmi Fine Chemical, another group company, produces active pharmaceutical ingredients for major drugmakers.

In July 2015, Hanmi announced a partnership with German drugmaker Boehringer Ingelheim. The duo aims to develop a pharmaceutical candidate, HM61713, into a new molecularly targeted drug for lung cancer treatment. Hanmi is to put the drug through clinical trials in South Korea, China and Hong Kong, as well as handle sales licensing, production and commercialization in those markets.

Under the deal, Hanmi will start by using $50 million in contract money to conduct clinical development. The South Korean company stands to receive a total of $730 million, based on progress with licensing and other tasks.

In the news

Financial highlights

Dec 2017

  • Local currency
  • US Dollar
Revenue 652,324.36M
Gross profit --
Operating income 39,694.91M
Income before tax 34,021.67M
Net income 31,441.81M
Diluted EPS --
Dividends per share --
Total assets 948,956.73M
Total liabilities 273,630.93M
Total equity 675,325.8M
Operating cash flow --

Currency in KRW

Revenue 577.01M
Gross profit --
Operating income 35.11M
Income before tax 30.09M
Net income 27.81M
Diluted EPS --
Dividends per share --
Total assets 886.41M
Total liabilities 255.59M
Total equity 630.82M
Operating cash flow --

Currency in USD

Valuation measures

Dec 2017

PER 224.26
ROA 3.27%
ROE 4.76%
Operating margin 6.08%
Profit margin 4.81%

Key executive

  • Co-President, Co-CEO & Director: Sae-Chang Kwon
  • Co-President, Co-CEO & Director: Jong-Soo Woo
  • Co-President & Director: Jong-Yoon Lim
  • Director & Vice President: Jae-Sik Kim
  • Executive Board Member: Yu-Shik Hwang

Share holders

  • LIM SUNG-GI(34.2%)
  • SHIN DONG-GUK(12.1%)
  • Hanmi IT(6.4%)
  • LIM JONG YOON(3.6%)
  • LIM JU-HYUN(3.5%)
  • LIM JONG-HOON(3.1%)
  • Hanmi Science Co., Ltd.(2.2%)
  • LIM JIN-HEE(2.2%)


  • Website:
  • Address: 214 Muha-ro, Paltan-myeon, Hwaseong-si, 18536, South Korea
  • Phone: +82.31.350.5600

Copyright © 2018 FactSet Research Systems Inc. All rights reserved.